| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.097 | 0.005 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.006 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.008 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.36 | 0.01 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |